You are here

FDA Says “No” to Hyperkalemia Drug

Manufacturing issues sink ZS-9 application

The FDA has issued a complete response letter (CRL) regarding the new drug application for ZS-9 (sodium zirconium cyclosilicate, ZS Pharma/AstraZeneca), an investigational medication being developed for the treatment of patients with hyperkalemia. The CRL refers to observations arising from a pre-approval manufacturing inspection. The FDA also acknowledged the receipt of recently submitted manufacturing data, which it has yet to review. The CRL does not require the generation of new clinical data.

ZS-9 is an insoluble, nonabsorbed compound with a structure that was designed to preferentially trap potassium ions. In in vitro studies, the potassium selectivity of ZS-9 resulted in a high binding capacity for potassium ions in the presence of other competing ions. ZS-9 has been studied in three double-blind, placebo-controlled trials and in one ongoing 12-month open-label trial in patients with hyperkalemia, representing more than 1,600 treated patients. ZS-9 is an investigational product that is not currently approved for any indication in any market.

The FDA’s decision came as a big surprise to AstraZeneca, according to a report from FierceBiotech. Last year, the company paid $2.7 billion for ZS Pharma to gain access to ZS-9. The drug was being positioned to grab some of the hyperkalemia market away from Relypsa Inc.’s Veltassa (patiromer).

Hyperkalemia (potassium levels of greater than 5.0 mEq/L in the blood serum) occurs in 23% to 47% of patients with advanced chronic kidney disease and/or chronic heart failure, and may lead to cardiac arrest and death. Up to 30% of patients with severe hyperkalemia may die if the disorder isn’t treated rapidly. Treatment with common heart medications (renin–angiotensin–aldosterone system [RAAS] inhibitors) can also be responsible for hyperkalemia. Current therapeutic options are limited, resulting in a significant unmet medical need.

Sources: AstraZeneca; May 27, 2016; and FierceBiotech; May 27, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress